Product Description
NEO6860 is a TRPV1 antagonist when activated by capsaicin but not by heat or pH, developed to relieve pain without the adverse events reported with nonmodality-selective TRPV1 antagonists.
Mechanisms of Action: TRPV1 Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neomed Institute
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NEO6860-OA-01 | P2 |
Completed |
Osteoarthritis, Knee |
2016-11-17 |
|
| NEO6860 | P1 |
Completed |
Osteoarthritis, Knee |
2015-07-01 |